{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:23:22Z","timestamp":1768433002622,"version":"3.49.0"},"reference-count":63,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chronic hepatitis C virus (HCV) infection causes hepatocellular carcinoma (HCC). Although HCV clearance has been improved by the advent of direct-acting antiviral agents (DAA), retrospective studies have shown that the risk of subsequent HCC, while considerably decreased compared with active HCV infection, persists after DAA regimens. However, either the mechanisms of how chronic HCV infection causes HCC or the factors responsible for HCC development after viral eradication in patients with DAA treatments remain elusive. We reported an in vitro model of chronic HCV infection and determined Wnt\/\u03b2-catenin signaling activation due to the inhibition of GSK-3\u03b2 activity via serine 9 phosphorylation (p-ser9-GSK-3\u03b2) leading to stable non-phosphorylated \u03b2-catenin. Immunohistochemical staining demonstrated the upregulation of both \u03b2-catenin and p-Ser9-GSK-3\u03b2 in HCV-induced HCC tissues. Chronic HCV infection increased proliferation and colony-forming ability, but knockdown of \u03b2-catenin decreased proliferation and increased apoptosis. Unexpectedly, Wnt\/\u03b2-catenin signaling remained activated in chronic HCV-infected cells after HCV eradication by DAA, but metformin reversed it through PKA\/GSK-3\u03b2-mediated \u03b2-catenin degradation, inhibited colony-forming ability and proliferation, and increased apoptosis, suggesting that DAA therapy in combination with metformin may be a novel therapy to treat HCV-associated HCC where metformin suppresses Wnt\/\u03b2-catenin signaling for HCV-infected patients.<\/jats:p>","DOI":"10.3390\/cells10040790","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T04:13:51Z","timestamp":1617336831000},"page":"790","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Additional Inhibition of Wnt\/\u03b2-Catenin Signaling by Metformin in DAA Treatments as a Novel Therapeutic Strategy for HCV-Infected Patients"],"prefix":"10.3390","volume":"10","author":[{"given":"Dong","family":"Lin","sequence":"first","affiliation":[{"name":"Laboratory Medicine and Department of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venu","family":"Reddy","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Department of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanadi","family":"Osman","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Department of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-5034","authenticated-orcid":false,"given":"Adriana","family":"Lopez","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Department of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-5951","authenticated-orcid":false,"given":"Ali Riza","family":"Koksal","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Department of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadeq Mutlab","family":"Rhadhi","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Department of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanta","family":"Dash","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Department of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-6296","authenticated-orcid":false,"given":"Yucel","family":"Aydin","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Department of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14218\/JCTH.2017.00067","article-title":"Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review","volume":"6","author":"Axley","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3350\/cmh.2012.18.4.347","article-title":"Hepatitis C virus and hepatocarcinogenesis","volume":"18","author":"Jeong","year":"2012","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4254\/wjh.v9.i36.1305","article-title":"Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection","volume":"9","author":"Irshad","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4161\/epi.4.5.9371","article-title":"Epigenetic disruption of the WNT\/beta-catenin signaling pathway in human cancers","volume":"4","author":"Ying","year":"2009","journal-title":"Epigenetics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1476-4598-9-25","article-title":"Axin downregulates TCF-4 transcription via beta-catenin, but not p53, and inhibits the proliferation and invasion of lung cancer cells","volume":"9","author":"Yang","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/carcin\/bgs371","article-title":"MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt\/beta-catenin signaling pathway","volume":"34","author":"Hsieh","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hallett, R.M., Kondratyev, M.K., Giacomelli, A.O., Nixon, A.M., Girgis-Gabardo, A., Ilieva, D., and Hassell, J.A. (2012). Small molecule antagonists of the Wnt\/beta-catenin signaling pathway target breast tumor-initiating cells in a Her2\/Neu mouse model of breast cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033976"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2045-3701-1-4","article-title":"Wnt\/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma","volume":"1","author":"Ji","year":"2011","journal-title":"Cell Biosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1073\/pnas.0811902106","article-title":"Activated Wnt\/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model","volume":"106","author":"Chien","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gut.2004.048132","article-title":"Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome","volume":"54","author":"Johnson","year":"2005","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/s41467-019-09780-z","article-title":"Promotion of growth factor signaling as a critical function of beta-catenin during HCC progression","volume":"10","author":"Kim","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2893.2000.00201.x","article-title":"Properties of the hepatitis C virus core protein: A structural protein that modulates cellular processes","volume":"7","author":"McLauchlan","year":"2000","journal-title":"J. Viral. Hepat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1574-6968.2001.tb10796.x","article-title":"Hepatitis C virus core protein: Intriguing properties and functional relevance","volume":"202","author":"Ray","year":"2001","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/hep.20668","article-title":"Hepatitis C virus core protein stimulates hepatocyte growth: Correlation with upregulation of wnt-1 expression","volume":"41","author":"Fukutomi","year":"2005","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Liu, J., Ding, X., Tang, J., Cao, Y., Hu, P., Zhou, F., Shan, X., Cai, X., Chen, Q., and Ling, N. (2011). Enhancement of canonical Wnt\/beta-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027496"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1743-422X-11-117","article-title":"Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus-induced multistep hepatocarcinogenesis","volume":"11","author":"Umer","year":"2014","journal-title":"Virol. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1038\/onc.2013.225","article-title":"Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition","volume":"33","author":"Quan","year":"2014","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virusres.2011.05.014","article-title":"Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCV core protein","volume":"160","author":"Ripoli","year":"2011","journal-title":"Virus Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12232","DOI":"10.1074\/jbc.M312245200","article-title":"The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade","volume":"279","author":"Street","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1099\/vir.0.80204-0","article-title":"Hepatitis C virus NS5A: Tales of a promiscuous protein","volume":"85","author":"Macdonald","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1128\/JVI.79.8.5006-5016.2005","article-title":"Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription","volume":"79","author":"Street","year":"2005","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2009.06.026","article-title":"Nonstructural 5A protein activates beta-catenin signaling cascades: Implication of hepatitis C virus-induced liver pathogenesis","volume":"51","author":"Park","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Transl. Int. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cld.2012.09.006","article-title":"HCV NS5A inhibitors in development","volume":"17","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1478-3231.2011.02699.x","article-title":"Direct acting antivirals for the treatment of chronic hepatitis C: One pill a day for tomorrow","volume":"32","author":"Asselah","year":"2012","journal-title":"Liver Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/13543784.2013.826189","article-title":"NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection","volume":"22","author":"Herbst","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11901-018-0424-8","article-title":"The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk","volume":"17","author":"Su","year":"2018","journal-title":"Curr. Hepatol. Rep"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1007\/s10620-019-05641-3","article-title":"Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents","volume":"64","author":"Zou","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2016.07.027","article-title":"High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis","volume":"65","author":"Cardoso","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2017.07.007","article-title":"Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study","volume":"67","author":"Kolly","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jhep.2016.06.009","article-title":"Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment","volume":"65","author":"Kozbial","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"Nagata","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/jvh.12726","article-title":"The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience","volume":"24","author":"Bielen","year":"2017","journal-title":"J. Viral. Hepat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2016.05.034","article-title":"Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment","volume":"65","author":"Torres","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.2147\/CMAR.S200059","article-title":"The beneficial effects of metformin on cancer prevention and therapy: A comprehensive review of recent advances","volume":"11","author":"Saraei","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.bbrc.2014.04.031","article-title":"Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells","volume":"447","author":"Aw","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cheng, J., Huang, T., Li, Y., Guo, Y., Zhu, Y., Wang, Q., Tan, X., Chen, W., Zhang, Y., and Cheng, W. (2014). AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093256"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ajpath.2013.10.005","article-title":"HCV infection selectively impairs type I but not type III IFN signaling","volume":"184","author":"Chandra","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"40019","DOI":"10.18632\/oncotarget.16685","article-title":"Chaperone-mediated autophagy compensates for impaired macroautophagy in the cirrhotic liver to promote hepatocellular carcinoma","volume":"8","author":"Chava","year":"2017","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.20518","article-title":"Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"41","author":"Radkowski","year":"2005","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0168-8278(99)80336-5","article-title":"Low HCV replication levels in end-stage hepatitis C virus-related liver disease","volume":"31","author":"Duvoux","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0272-6386(00)70310-6","article-title":"Biological dynamics of viral load in hemodialysis patients with hepatitis C virus","volume":"35","author":"Fabrizi","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/emboj\/16.13.3797","article-title":"beta-catenin is a target for the ubiquitin-proteasome pathway","volume":"16","author":"Aberle","year":"1997","journal-title":"EMBO J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1038\/sj.onc.1206118","article-title":"New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism","volume":"21","author":"Cadoret","year":"2002","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1179299X16684640","article-title":"Biomarkers for Hepatocellular Carcinoma","volume":"9","author":"Lou","year":"2017","journal-title":"Biomark Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhang, J., Chen, G., Zhang, P., Li, X., Gan, D., Cao, X., Han, M., Du, H., and Ye, Y. (2020). The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228857"},{"key":"ref_52","first-page":"2695","article-title":"Metformin-activated AMPK regulates beta-catenin to reduce cell proliferation in colon carcinoma RKO cells","volume":"17","author":"Park","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41421-018-0033-2","article-title":"Cancer cell specific inhibition of Wnt\/beta-catenin signaling by forced intracellular acidification","volume":"4","author":"Melnik","year":"2018","journal-title":"Cell Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4254\/wjh.v10.i9.595","article-title":"Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review","volume":"10","author":"Gigi","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.mehy.2008.10.039","article-title":"Epigenetic side-effects of common pharmaceuticals: A potential new field in medicine and pharmacology","volume":"73","author":"Csoka","year":"2009","journal-title":"Med. Hypotheses"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fcell.2014.00049","article-title":"Epigenetics across the human lifespan","volume":"2","author":"Kanherkar","year":"2014","journal-title":"Front Cell Dev. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1111\/liv.13872","article-title":"Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes","volume":"38","author":"Tseng","year":"2018","journal-title":"Liver Int."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Cunha, V., Cotrim, H.P., Rocha, R., Carvalho, K., and Lins-Kusterer, L. (2019). Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann. Hepatol.","DOI":"10.1016\/j.aohep.2019.10.005"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1158\/1940-6207.CAPR-10-0186","article-title":"Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial","volume":"3","author":"Hosono","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(15)00565-3","article-title":"Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: A multicentre double-blind, placebo-controlled, randomised phase 3 trial","volume":"17","author":"Higurashi","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s12032-011-9846-7","article-title":"Metformin and cancer: New applications for an old drug","volume":"29","author":"Kourelis","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/4\/790\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:26:05Z","timestamp":1760361965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/4\/790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cells10040790"],"URL":"https:\/\/doi.org\/10.3390\/cells10040790","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]}}}